Sudeep Pharma Q2 FY27 Financial Results

Revenue: Rs 196.70 crore (+20.9% YoY) | Profit: Rs 51.81 crore (+10.8% YoY)

Reader Takeaway: Strong revenue growth driven by pharma and nutrition segments; investors should watch for faster IPO capital deployment.

What just happened

Sudeep Pharma Ltd released its unaudited financial results for the quarter ended September 30, 2026. The company posted consolidated revenue from operations of Rs 196.70 crore, representing a 20.9% increase from Rs 162.67 crore in the same quarter last year. Consolidated net profit for the period rose to Rs 51.81 crore, compared to Rs 46.78 crore in the year-ago period.

Why this matters

The steady growth in both top and bottom lines indicates sustained demand for the company’s core offerings. Standalone performance was particularly robust, with standalone profit jumping to Rs 42.34 crore from Rs 29.74 crore in Q2 FY26. The pharmaceutical, food, and nutrition segment emerged as a significant contributor, with segment revenue rising to Rs 142.50 crore.

IPO Proceeds Utilization

As of September 30, 2026, the company has utilized Rs 32.53 crore out of the total net IPO proceeds of Rs 88.34 crore. The remaining Rs 55.81 crore is held in bank term deposits. The pace of this capital deployment remains a key point of interest for shareholders as it reflects the company's progress on expansion plans.

Corporate and Governance

The board of directors approved the financial statements on October 28, 2026. The statutory auditors, B S R and Co, conducted a limited review and issued an unmodified conclusion, confirming the transparency of the reported figures.